Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 08, 2015 7:09 PM ET


Company Overview of New Haven Pharmaceuticals, Inc.

Company Overview

New Haven Pharmaceuticals, Inc. develops prescription pharmaceuticals that utilize currently marketed drugs or generally recognized as safe active pharmaceutical ingredients for therapeutic applications. It offers NHP-554C, an anti-platelet aspirin product for patients at higher risk for a secondary stroke/acute cardiac event that slowly releases into the bloodstream over 24 hours; NHP-554CZ, an anti-platelet aspirin product incorporating Yale University technology utilizing zinc salts; and NHP-229 for the purpose of lowering stomach acid alone or in combination with other drugs. The company was founded in 2008 and is based in New Haven, Connecticut.

142 Temple Street

Suite 205

New Haven, CT 06510

United States

Founded in 2008

Key Executives for New Haven Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 67
Co-Founder and Executive Chairman
Age: 70
Executive Vice President of Operations and Director
Age: 51
Chief Business Officer
Vice President of Regulatory Affairs
Age: 62
Compensation as of Fiscal Year 2015.

New Haven Pharmaceuticals, Inc. Key Developments

New Haven Pharmaceuticals Receives FDA Approval for DURLAZA Extended Release Capsules for Secondary Prevention of Stroke and Acute Cardiac Events

New Haven Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved DURLAZA (aspirin), the first and only 24-hour, Extended Release Capsules, (162.5mg) for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack). Low-dose aspirin has been proven to reduce the risk of secondary cardiovascular events and mortality in high-risk patients with stable cardiovascular disease. This is primarily due to aspirin's ability to inhibit platelet aggregation (blood clotting). While the body is making platelets 24-hours a day, current immediate-release traditional aspirin only stays in the blood for about a mean duration of four to six hours, with peak plasma concentrations peaking after just 30 minutes. DURLAZA utilizes extended-release, microcapsule technology to prolong aspirin release. DURLAZA offers the only once-daily, 24- hour antiplatelet therapy through the extended release of its 162.5mg dose, resulting in prolonged absorption, and sustained platelet exposure to aspirin. DURLAZA, like immediate-release aspirin, increases the risk of bleeding and gastric ulceration, and may cause fetal harm when administered to a pregnant woman.

New Haven Pharmaceuticals, Inc. Announces Executive Appointments

New Haven Pharmaceuticals, Inc. has strengthened its management team with the appointment of two experienced pharmaceutical executives to newly-created positions: Dr. Jeffrey Patrick as Chief Scientific Officer, and Michael Richardson as Chief Business Officer. Jeff Patrick, Pharm.D., joins NHP from Mallinckrodt Pharmaceuticals (formerly Covidien), where he most recently was Global Vice President of Medical Affairs. Mr. Richardson joins NHP from Grünenthal USA, where he served most recently as Head of Commercial Affairs.

New Haven Pharmaceuticals, Inc. Appoints Larry Dillaha as Executive Vice President Operations

New Haven Pharmaceuticals, Inc. announced the appointment of Larry Dillaha, M.D., to the newly-created position of Executive Vice President Operations. Dr. Dillaha joins the company from Insys Therapeutics, Inc. where he served as Chief Medical Officer since April 2010. Prior to joining New Haven Pharmaceuticals, Dr. Dillaha served as Chief Medical Officer of Insys Therapeutics.

Similar Private Companies By Industry

Company Name Region
LQ3 Pharmaceuticals, Inc. United States
AMS Health Sciences, Inc. United States
Zurex Pharma, Inc. United States
Forbes Medi-Tech (Research) Inc. United States
Tamarack Biotics LLC United States

Recent Private Companies Transactions

Private Placement
October 6, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact New Haven Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at